Fulcrum Therapeutics Inc
Change company Symbol lookup
Select an option...
FULC Fulcrum Therapeutics Inc
GOOG Alphabet Inc
WHLR Wheeler Real Estate Investment Trust Inc
FRHLF Freehold Royalties Ltd
CTNT Cheetah Net Supply Chain Service Inc
LASE Laser Photonics Corp
GFR M3-Brigade Acquisition III Corp
PCT Purecycle Technologies Inc
UPST Upstart Holdings Inc
CPSI Computer Programs and Systems Inc
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). The Company has developed a product engine to identify and validate cellular drug targets that can modulate gene expression to treat known root causes of genetically defined diseases. The Company’s product engine integrates patient-derived tissue and disease-relevant cell models that it interrogates using its pharmacologically diverse and annotated small-molecule compound library and customized CRISPR and RNAi libraries.

Closing Price
$4.17
Day's Change
0.08 (1.96%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.22
Day's Low
4.05
Volume
(Light)
Volume:
398,577

10-day average volume:
753,614
398,577
  • Prev Close
    4.09
  • Today's Open
    4.21
  • Day's Range
    4.05-4.22
  • Avg Vol (10-day)
    753.6K
  • Last (time)
    4:00p ET 09/22/23
  • Last (size)
    10
  • 52-Wk Range
    2.25 - 15.00
    LowHigh
  • (01/13/23 - 04/12/23)
    85.33%
  • 123.1%
  • Market Cap
    257.8M
  • Shares Outstanding
    61.8M
  • -1.81
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 2.1
  • 84.12
  • (% of float 08/31/23)
    5.84

Latest News

September 22, 2023
8:00 am ET
Globe Newswire
September 15, 2023
4:30 pm ET
Globe Newswire
September 13, 2023
9:01 am ET
PR Newswire
September 09, 2023
7:00 pm ET
Globe Newswire
September 07, 2023
8:01 am ET
Globe Newswire
August 25, 2023
8:16 am ET
Zacks
August 24, 2023
9:15 am ET
Zacks
7:42 am ET
Zacks
August 22, 2023
9:31 am ET
PR Newswire
8:01 am ET
MarketWatch
8:00 am ET
MarketWatch
7:00 am ET
Globe Newswire
August 11, 2023
4:53 pm ET
Globe Newswire
August 03, 2023
7:01 am ET
Globe Newswire
6:55 am ET
Globe Newswire
July 27, 2023
7:00 am ET
Globe Newswire
July 10, 2023
7:00 am ET
Globe Newswire
July 07, 2023
5:30 pm ET
Globe Newswire
June 27, 2023
2:43 pm ET
Accesswire
1:01 pm ET
Globe Newswire
12:50 pm ET
Globe Newswire
12:30 pm ET
Newsfile
10:00 am ET
Newsfile
7:31 am ET
Newsfile
5:45 am ET
PR Newswire
June 26, 2023
1:01 pm ET
Globe Newswire
12:35 pm ET
Globe Newswire
12:26 pm ET
Newsfile
12:17 pm ET
BusinessWire
10:00 am ET
Accesswire
7:30 am ET
Newsfile
5:45 am ET
PR Newswire
12:01 am ET
Globe Newswire
June 25, 2023
9:00 pm ET
Globe Newswire
11:00 am ET
PR Newswire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.